Skip to main content
SpringerLink
Log in

Long-term use of systemic azole antifungals can result in hepatotoxicity and other serious adverse effects

  • Drug Reactions and Interactions
  • Published:
Drugs & Therapy Perspectives Aims and scope Submit manuscript

Abstract

Long-term use of systemic azole antifungals (i.e. fluconazole, isavuconazole, itraconazole, ketoconazole, posaconazole and voriconazole) can result in serious adverse drug effects (ADEs), such as hepatotoxicity and cardiac effects. Cytochrome P450 inhibition by azoles contributes to many ADEs, such as adrenal insufficiency due to hormone disruption, while pharmacokinetic interactions can lead to myositis or peripheral neuropathy. Other notable ADEs include pancreatitis, bone pain, renal failure, skin cancer and Stevens-Johnsons syndrome. ADEs may be managed with monitoring, adjusting dosages and switching azoles.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Diflucan (fluconazole): UK summary of product characteristics. Sandwich: Pfizer Limited; 2019.

  2. Diflucan® (fluconazole): US prescribing information. New York: Pfizer Inc.; 2019.

  3. Cresemba (isavuconazole): EU summary of product characteristics. Lörrach: Basilea Pharmaceutica Deutschland GmbH; 2019.

  4. Cresemba® (isavuconazole) US prescribing information. Northbrook (IL): Astellas Pharma US, Inc.; 2018.

  5. Itraconazole: UK summary of product characteristics. Measham: Beacon Pharmaceuticals Limited; 2019.

  6. Sporanox® (itraconazole): US prescribing information. Titusville (NJ): Janssen Pharmaceuticals, Inc.; 2019.

  7. Ketoconazole tablet: US prescribing information. Morgantown (WV): Mylan Pharmaceuticals, Inc.; 2018.

  8. Noxafil (posaconazole): EU summary of product characteristics. Haarlem: Merck Sharp & Dohme B.V.; 2019.

  9. Noxafil® (posaconazole): US prescribing information. Whitehouse Station (NJ): Merck Sharp & Dohme Corp.; 2019.

  10. Vfend (voriconazole): EU summary of product characteristics. Bruxelles: Pfizer Europe MA EEIG; 2019.

  11. Vfend® (voriconazole): US prescribing information. New York: Pfizer, Inc.; 2019.

  12. Benitez LL, Carver PL. Adverse effects associated with long-term administration of azole antifungal agents. Drugs. 2019;79(8):833–53.

    Article  CAS  Google Scholar 

  13. Suspension of marketing authorisations for oral ketoconazole. London: European Medicines Agency; 2013.

Download references

Author information

Authors and Affiliations

    Consortia

    Adis Medical Writers

    Ethics declarations

    Conflict of interest

    The article was adapted from Drugs 2019;79(8):833–53 [12] by employees of Adis International Ltd./Springer Nature, who are responsible for the article content and declare no conflicts of interest.

    Funding

    The preparation of this review was not supported by any external funding.

    Rights and permissions

    Reprints and permissions

    About this article

    Check for updates. Verify currency and authenticity via CrossMark

    Cite this article

    Adis Medical Writers. Long-term use of systemic azole antifungals can result in hepatotoxicity and other serious adverse effects. Drugs Ther Perspect 36, 112–115 (2020). https://doi.org/10.1007/s40267-019-00699-5

    Download citation

    • Published:

    • Issue Date:

    • DOI: https://doi.org/10.1007/s40267-019-00699-5

    Search

    Navigation